美国退行性二尖瓣反流的外科与经导管介入治疗
基于美国2012至2019年医保数据,分析53,117例退行性二尖瓣反流干预(外科修复或TEER)的趋势与3年结局。匹配4532对后,TEER组3年生存率65.9%低于外科组85.7%,心衰再入院和再干预率更高,卒中率无显著差异。
要点
- 退行性二尖瓣反流总干预量2012至2019年无显著变化(P=.18),外科病例减少约三分之一而TEER增加。
- 匹配后TEER组3年生存率65.9%低于外科组85.7%(P<.001)。
- 匹配后TEER组心衰再入院率17.8%高于外科组11.2%,再干预率6.1%高于外科组1.3%(均P<.001)。
核心结论
- 在退行性二尖瓣反流的医保受益人中,TEER使用增加与更差的生存、更多心衰再入院和更多二尖瓣再干预相关。
- 需要随机试验来更好地指导治疗选择。
研究设计与样本
- 基于美国Centers for Medicare and Medicaid Services数据(2012至2019年)的分析,共纳入53,117例因退行性二尖瓣反流接受二尖瓣干预(外科或TEER)的患者,中位随访2.9年(四分位距1.2至5.1年)。
主要发现
- 2012至2019年总年度二尖瓣干预量无显著变化(P=.18),但外科病例减少约三分之一,TEER增加。
- 在27,170例接受TEER(n=7755)或外科修复(n=19415)的患者中,外科患者更年轻(71.8岁 vs 80.8岁;P<.001),合并症和衰弱更少。
- 在4532对按年龄、衰弱和合并症匹配的患者中,TEER后3年生存率为65.9%(95%CI 64.3%-67.6%),外科后为85.7%(95%CI 84.5%-86.9%)(P<.001)。
- 匹配后3年卒中率TEER组为1.8%(95%CI 1.5%-2.2%),外科组为2.0%(95%CI 1.6%-2.4%)(P=.49)。
- 匹配后3年心衰再入院率TEER组为17.8%(95%CI 16.7%-18.9%),外科组为11.2%(95%CI 10.3%-12.2%)(P<.001);二尖瓣再干预率TEER组为6.1%(95%CI 5.5%-6.9%),外科组为1.3%(95%CI 1.0%-1.7%)(P<.001)。
临床怎么用
- 原文结论指出,在退行性二尖瓣反流的医保受益人中,TEER使用增加与更差生存、更多心衰再入院和更多二尖瓣再干预相关,并认为需要随机试验来更好地指导治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated practice trends and 3-year outcomes of transcatheter edge-to-edge repair (TEER) and surgical repair for degenerative mitral regurgitation in the United States. METHODS: From the Centers for Medicare and Medicaid Services data (2012-2019), 53,117 mitral valve interventions (surgery or TEER) were performed for degenerative mitral regurgitation, identified by excluding rheumatic and congenital disease, endocarditis, myocardial infarction, cardiomyopathy, and concomitant or prior coronary revascularizations. Median follow-up was 2.9 years (interquartile range, 1.2-5.1 years). End points were 3-year survival, stroke, mitral reinterventions, and heart failure readmissions. RESULTS: Volume of total annual mitral interventions did not significantly change (P = .18) between 2012 and 2019. However, surgical cases decreased by one-third, whereas TEER increased. Among 27,170 patients (52.5% men; mean age, 73.5 years) who underwent TEER (n = 7755) or surgical repair (n = 19,415), surgical patients were younger (71.8 vs 80.8 years; P < .001), with less comorbidity and frailty. In 4532 patient pairs matched for age, frailty, and comorbidity, 3-year survival after TEER was 65.9% (95% CI, 64.3%-67.6%) and 85.7% (95% CI, 84.5%-86.9%) after surgery (P < .001). Three years after TEER or surgery, stroke rates were 1.8% (95% CI, 1.5%-2.2%) and 2.0% (95% CI, 1.6%-2.4%) (P = .49); heart failure readmission rates were 17.8% (95% CI, 16.7%-18.9%) and 11.2% (95% CI, 10.3%-12.2%) (P < .001); and mitral reintervention rates were 6.1% (95% CI, 5.5%-6.9%) and 1.3% (95% CI, 1.0%-1.7%) (P < .001), respectively. CONCLUSIONS: Among Medicare beneficiaries with degenerative mitral regurgitation, an increase in TEER utilization was associated with worse survival, increased heart failure readmissions, and more mitral reinterventions. Randomized trials are needed to better inform treatment choice.
引用
- Chikwe J, Chen Q, Bowdish ME, et al. Surgery and transcatheter intervention for degenerative mitral regurgitation in the United States. J Thorac Cardiovasc Surg. 2024. PMID: 38237762. doi:10.1016/j.jtcvs.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。